May 13, 2008|
Commodity prices, Indian pharma and more...
Commodity prices on an uptick
Commodity prices continue to escalate and have turned out to be a major problem that the world has been facing after the subprime crisis, largely due to its impact on inflation. And dissecting these commodities further, what has been worrisome of late is the rising energy and food prices. The IMF has indicated several reasons why commodity prices have been charting an upward path. First is the demand generated by emerging economies for commodities, particularly oil. In the oil market, demand from China, India and the Middle East accounted for more than 56% of the growth in oil consumption during 2001-07 (Source: IMF). This surging demand for oil has been attributed to increasing ownership of vehicles following the rise in per capital incomes, and government policies, which involve subsiding prices at the retail level. The International Energy Agency has projected that oil consumption growth in emerging and developing economies would continue to outstrip such growth in advanced economies, increasing by about 3.5% a year during 2007-12, compared with the latter's 1%.
The second factor which has wielded a strong influence on the soaring commodity prices and thereby inflation has been food. The trend of food prices have once again been determined by the rise in income levels consequently spurring demand for food as well as increased focus on biofuel production. For instance, IMF states that as emerging economies become more affluent, they are not only consuming more food but are shifting their diet toward high-protein foods such as meat, seafood, edible oils and fruits and vegetables. Further, emphasis on biodiesel production has been created anomalies in the availability of food thereby fuelling price hikes. To put things into perspective, 20% to 50% of feedstocks, especially corn and rapeseed, in major producing countries are being diverted from food to biofuels.
Other factors that have contributed to the rise in commodity prices worldwide have been lower interest rates and the depreciating US dollar. Given that most of the commodities namely crude oil, metals and foodgrains are priced in US dollars, any depreciation in the latter makes commodities less expensive for countries outside the dollar area. Also, since there is a time lag before supply catches up with demand, firm commodity prices are expected to persist in the near term atleast, a situation that will keep governments around the world on their toes in a bid to contain inflation.
Read how inflation is hurting us
Co-development for the futureRead our view on pharma out-licensing
Ranbaxy's recent collaboration with Merck highlights the growing emphasis that domestic pharma companies are laying on co-development of new chemical entities (NCEs). For domestic companies, such an arrangement is to their advantage as it enables them to leverage on the expertise of the innovator and also share expenses against a backdrop of rising R&D costs. For innovator companies, shifting clinical trials in early stages to low cost destinations like India enhances the prospect of improving profitability, the latter being under a cloud due to ballooning R&D costs and less number of new product approvals. In recent times, domestic companies have been very proactive in inking collaboration deals with global innovators; Nicholas Piramal's agreement with Eli Lilly and Ranbaxy's collaboration with GSK Plc are some examples to be noted. Having said that, the impact of such deals will be negligible on those domestic companies, which are hiving or have hived off their R&D units into separate companies.
More Views on News
Jun 10, 2017
Forty Indian investing gurus, as worthy of imitation as the legendary Peter Lynch, can help you get rich in the stock market.
Aug 21, 2017
PersonalFN explains the chief factor pushing gold prices up of late.
Aug 21, 2017
One of the hallmarks of successful investing is to look out for companies that have a unique and enduring moat.
Aug 19, 2017
Ever heard of Lindy Effect? Find out how you can use it to pick timeless stocks.
Aug 18, 2017
Buying the index now will hardly help make money in stocks even in ten years.
More Views on News
Aug 10, 2017
Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.
Aug 8, 2017
'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'
Aug 8, 2017
Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...
Aug 12, 2017
The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.
Aug 10, 2017
Bitcoin hits an all-time high, is there more upside left?
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407